Risk higher for cardiovascular disease, diabetes, renal mortality; lower risk for cancer mortality
No increase in serious hypoglycemia, hyperglycemia after switch from analogue to human insulin
In a Finnish study, the cumulative risk for end-stage renal disease among patients with newly diagnosed with type 2 diabetes was less than 1% at 20 years.
Currently, there is no effective generic alternative to brand-name insulin
Suppressing albuminuria should be an important target of therapy, according to investigators.
Recommendations suggest doctors prescribe individualized exercise training for these patients
Reduction in risk for range of critical outcomes greatest for daily dietary fiber intake of 25 to 29 g.
Rate of the primary outcome was similar for canagliflozin, glucagon-like peptide-1 agonist
Cardiovascular risk increased with sulfonylureas and basal insulin versus newer classes of ADM
17.1% of patients reported having experienced one or more events in previous year.